The Use of IO Doublet in PD-L1-Negative NSCLC

David Carbone

Year in Review: Lung Cancer

Balazs Halmos

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

Vogl,NY on How to Ask Good Questions at Medical Meetings

Vogl, NY

S. Vogl

Cancer Screening Molecular Tools

Fengting Yan

ESMO 2024 Insights: Treatment Rechallenge After Grade 1 Trastuzumab-…

2024 ESMO Annual Meeting Insights Hub

K. Natsuhara

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

WCLC 2024 Insights: Optimal Management of Malignant Pleural Effusion

Insights from 2024 WCLC

P. Lee

Staging Disease: How Oncologists Stage NSCLC

GRACE

I. Dagogo-Jack, M. Das, C. Jeffrey Yang

ASCO® 2024 Lung Cancer Highlights: CROWN, LAURA, ADRIATIC, and PALOM…

2024 ASCO® Annual Meeting Insights Hub

L. Raez

2024 Updates on NSCLC Targeted Therapies: FLAURA2 Trial - Osimertini…

Yale Cancer Center

P. Janne

ASCO® 2024 Precision Medicine Highlights: LAURA and CROWN Trials (NS…

2024 ASCO® Annual Meeting Insights Hub

V. Subbiah

2024 Updates on the Fast-Changing NSCLC Landscape

Total Health

R. Osarogiagbon

NSCLC & Targeted Therapy: A Brief Overview and Update in the Metasta…

Memorial Sloan Kettering Cancer Center

M. Hwang

NGS and Liquid Biopsy: Overcoming Challenges in Widespread Testing

Total Health

S. Kazmi

ASCO® 2024 Lung Cancer Roundtable: Advances in NSCLC

ecancer

E. Felip, A. Spira, A. Passaro, A. Addeo

Year in Review: Precision Medicine

Vivek Subbiah

WCLC 2024 Insights: MARIPOSA - Amivantamab + Lazertinib vs. Osimerti…

Insights from 2024 WCLC

S. Gadgeel

Duration of Immunotherapy Beyond 2 Years for Patients With Advanced …

IASLC Targeted Therapies of Lung Cancer 2023 Conference Coverage

E. Rodriguez

ASCO® 2024 Insights: "KRYSTAL-12 Study - Adagrasib vs. Docetaxel in …

2024 ASCO® Annual Meeting Insights Hub

T. Mok